UCB (OTCMKTS:UCBJY) Stock Rating Upgraded by Jefferies Financial Group

UCB (OTCMKTS:UCBJY) was upgraded by Jefferies Financial Group to a “moderate sell” rating in a report released on Monday,Zacks.com reports.

Other research analysts have also recently issued reports about the company. Zacks Research cut UCB from a “hold” rating to a “strong sell” rating in a research note on Thursday, June 11th. Wolfe Research raised UCB to a “strong-buy” rating in a research note on Monday, February 23rd. Finally, Barclays downgraded UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, UCB currently has a consensus rating of “Hold”.

UCB Price Performance

Shares of UCBJY stock opened at $143.03 on Monday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. The firm’s 50 day moving average price is $144.16 and its 200-day moving average price is $147.52. UCB has a one year low of $94.75 and a one year high of $168.76.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.